- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Mesoblast Ltd (MESO)
Track today's live Mesoblast (MESO) share price, performance and key data on this page with our current NASDAQ:MESO stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Mesoblast share price on the NASDAQ exchange. Use the dropdown to switch exchange for the MESO share price, head to our technical summary section, which provides analysis on Mesoblast share price buy/sell indicators using real-time data (or discuss the Mesoblast (MESO) stock price today with other investors in the Mesoblast NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:MESO share price (ISIN: US5907174016) to enhance your trading decisions with our free investment tools and resources.
What Is the Mesoblast Ltd Share Price Today?
The Mesoblast share price today is 14.280.
What Is the Stock Symbol for Mesoblast Ltd
The stock symbol (or 'ticker') for Mesoblast Ltd is "MESO."
What Stock Exchange Does Mesoblast Ltd Trade On?
Mesoblast Ltd is listed and trades on the NASDAQ stock exchange.
Is Mesoblast Ltd a Good Stock to Buy?
Determining whether Mesoblast (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:MESO share price (ISIN: US5907174016) to enhance your trading decisions with our free investment tools and resources.
What Is the Mesoblast Ltd Share Price Today?
The Mesoblast share price today is 14.280.
What Is the Stock Symbol for Mesoblast Ltd
The stock symbol (or 'ticker') for Mesoblast Ltd is "MESO."
What Stock Exchange Does Mesoblast Ltd Trade On?
Mesoblast Ltd is listed and trades on the NASDAQ stock exchange.
Is Mesoblast Ltd a Good Stock to Buy?
Determining whether Mesoblast (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Currency in USD
14.280
-0.050(-0.35%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.040
14.500
52 wk Range
10.350
21.500
MESO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.04014.500
52 wk Range
10.35021.500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MESO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
35.000
Upside
+145.10%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 35.000
(+145.10% Upside)
Mesoblast Ltd Earnings Call Summary for H1/2026
- Mesoblast reported H1 FY2026 revenue of $51.3M, driven by Ryoncil's $49M contribution and 93% gross margin performance.
- Net loss narrowed to $40.2M, improving $7.8M year-over-year despite higher R&D ($46.1M) and SG&A expenses ($28.5M, up 58%).
- Company secured $125M credit facility to enhance financial flexibility and support commercialization and R&D investments.
- Management projects improved operating cash flow usage in H2 FY2026 with continued Ryoncil revenue growth and cost discipline.
- Stock rose 1.18% to $17.11 in premarket trading; InvestingPro data shows 191% revenue surge but notes competitive and regulatory risks.
Last Updated: 26/02/2026, 22:56
Read Full TranscriptEarnings
Latest Release
02/06/2026
EPS / Forecast
-0.03 / -0.03
Revenue / Forecast
30.3M / 33.28M
Compare MESO to Peers and Sector
Metrics to compare | MESO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMESOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −19.4x | −1.9x | −0.4x | |
PEG Ratio | −0.98 | 0.00 | 0.00 | |
Price/Book | 3.2x | 1.6x | 2.6x | |
Price / LTM Sales | 28.0x | 2.4x | 3.1x | |
Upside (Analyst Target) | 144.2% | 169.2% | 48.3% | |
Fair Value Upside | Unlock | 6.9% | 6.1% | Unlock |
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Mesoblast (NASDAQ: MESO) Share Price Today?
The Mesoblast stock price today is 14.280 USD.
What Stock Exchange Does Mesoblast (MESO) Trade On?
Mesoblast is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Mesoblast?
The stock symbol (also called a 'ticker') for Mesoblast is "MESO."
What Is the Current Mesoblast Market Capitalisation?
As of today, Mesoblast (NASDAQ: MESO) market cap is 1.830B USD.
What Is Mesoblast's (MESO) Earnings Per Share (TTM)?
The Mesoblast EPS is currently -0.074 (Trailing Twelve Months).
When Is the Next Mesoblast Earnings Date?
Mesoblast's next earnings report will be released on 02/09/2026.
Is MESO a Buy or Sell From a Technical Analyst Perspective?
Based on today's Mesoblast moving averages and other technical indicators, the daily buy/sell signal for MESO stock is Neutral.
How Many Times Has Mesoblast Stock Split?
Mesoblast has split 1 times. (See the MESO stock split history page for full effective split date and price information.)
How Many Employees Does Mesoblast Have?
Mesoblast has 81 employees, based on their latest Companies House report.
What is the current trading status of Mesoblast (NASDAQ: MESO)?
As of 07/07/2026, Mesoblast (MESO) is trading at a share price of 14.280 USD, with a previous close of 14.330 USD. The stock has fluctuated within a day range of 14.040 USD to 14.500 USD, while its 52-week range spans from 10.350 USD to 21.500 USD.
What Is Mesoblast (MESO) Price Target According to Analysts?
The average 12-month price target for Mesoblast is 35.000 USD, with a high estimate of 35 USD and a low estimate of 35 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +145.10% Upside potential.
What Is the MESO Premarket Price?
MESO's last pre-market stock price is 14.270 USD. The pre-market share volume is 6,090.000, and the stock has decreased by -0.060, or -0.420%.
What Is the MESO After Hours Price?
MESO's last after hours stock price is 14.313 USD, the stock has decreased by -0.018, or -0.120%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.